APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS-C Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global IBS-C Drugs Market Analysis and Forecast 2026-2032

20 December 2025216 pages

Choose your research edition.

Industry ResearchIBS-C Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS-C Drugs Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS-C Drugs Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS-C Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global IBS-C Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for IBS-C Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for IBS-C Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for IBS-C Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for IBS-C Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of IBS-C Drugs include Abbott Laboratories, Actavis Nordic A/S, Albireo Pharma Inc, Ardelyx, Inc, Astellas Pharmaceuticals, Bama-Geve, SLU, Catalent Pharmaceuticals Solutions, Ferring BV and Ironwood Pharmaceuticals, Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for IBS-C Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of IBS-C Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for IBS-C Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the IBS-C Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global IBS-C Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for IBS-C Drugs sales, projected growth trends, production technology, application and end-user industry.

IBS-C Drugs Segment by Company

Abbott Laboratories

Actavis Nordic A/S

Albireo Pharma Inc

Ardelyx, Inc

Astellas Pharmaceuticals

Bama-Geve, SLU

Catalent Pharmaceuticals Solutions

Ferring BV

Ironwood Pharmaceuticals, Inc

Norgine B.V

Novartis Pharma Ag

Ono Pharmaceutical Co., Ltd

Prometheus Laboratories Inc

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Synthetic Biologics, Inc

Teva Pharmaceutical Industries

The Menarini Group

Yuhan Corp

Astrazeneca Plc

Nestle

IBS-C Drugs Segment by Type

Stimulant Laxatives

Linaclotide

Lubiprostone

Osmotic Laxatives

Others

IBS-C Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

IBS-C Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS-C Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS-C Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS-C Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of IBS-C Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IBS-C Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global IBS-C Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Stimulant Laxatives Major Manufacturers Table 3. Linaclotide Major Manufacturers Table 4. Lubiprostone Major Manufacturers Table 5. Osmotic Laxatives Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global IBS-C Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Pharmacies Major Manufacturers Table 9. Online Pharmacies Major Manufacturers Table 10. Retail Pharmacies Major Manufacturers Table 11. IBS-C Drugs Industry Trends Table 12. IBS-C Drugs Industry Drivers Table 13. IBS-C Drugs Industry Opportunities and Challenges Table 14. IBS-C Drugs Industry Restraints Table 15. Global IBS-C Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global IBS-C Drugs Revenue by Region (2021-2026) & (US$ Million) Table 17. Global IBS-C Drugs Revenue by Region (2027-2032) & (US$ Million) Table 18. Global IBS-C Drugs Revenue Market Share by Region (2021-2026) Table 19. Global IBS-C Drugs Revenue Market Share by Region (2027-2032) Table 20. Global IBS-C Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global IBS-C Drugs Sales by Region (2021-2026) & (K Units) Table 22. Global IBS-C Drugs Sales by Region (2027-2032) & (K Units) Table 23. Global IBS-C Drugs Sales Market Share by Region (2021-2026) Table 24. Global IBS-C Drugs Sales Market Share by Region (2027-2032) Table 25. Global IBS-C Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global IBS-C Drugs Revenue Market Share by Manufacturers (2021-2026) Table 27. Global IBS-C Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global IBS-C Drugs Sales Market Share by Manufacturers (2021-2026) Table 29. Global IBS-C Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global IBS-C Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global IBS-C Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global IBS-C Drugs Manufacturers, Product Type & Application Table 33. Global IBS-C Drugs Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global IBS-C Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global IBS-C Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 38. Global IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 39. Global IBS-C Drugs Revenue Market Share by Type (2021-2026) Table 40. Global IBS-C Drugs Revenue Market Share by Type (2027-2032) Table 41. Global IBS-C Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 43. Global IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 44. Global IBS-C Drugs Sales Market Share by Type (2021-2026) Table 45. Global IBS-C Drugs Sales Market Share by Type (2027-2032) Table 46. Global IBS-C Drugs Price by Type (2021-2026) & (US$/Unit) Table 47. Global IBS-C Drugs Price by Type (2027-2032) & (US$/Unit) Table 48. Global IBS-C Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 50. Global IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 51. Global IBS-C Drugs Revenue Market Share by Application (2021-2026) Table 52. Global IBS-C Drugs Revenue Market Share by Application (2027-2032) Table 53. Global IBS-C Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 55. Global IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 56. Global IBS-C Drugs Sales Market Share by Application (2021-2026) Table 57. Global IBS-C Drugs Sales Market Share by Application (2027-2032) Table 58. Global IBS-C Drugs Price by Application (2021-2026) & (US$/Unit) Table 59. Global IBS-C Drugs Price by Application (2027-2032) & (US$/Unit) Table 60. Abbott Laboratories Company Information Table 61. Abbott Laboratories Business Overview Table 62. Abbott Laboratories IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Abbott Laboratories IBS-C Drugs Product Portfolio Table 64. Abbott Laboratories Recent Development Table 65. Actavis Nordic A/S Company Information Table 66. Actavis Nordic A/S Business Overview Table 67. Actavis Nordic A/S IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Actavis Nordic A/S IBS-C Drugs Product Portfolio Table 69. Actavis Nordic A/S Recent Development Table 70. Albireo Pharma Inc Company Information Table 71. Albireo Pharma Inc Business Overview Table 72. Albireo Pharma Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Albireo Pharma Inc IBS-C Drugs Product Portfolio Table 74. Albireo Pharma Inc Recent Development Table 75. Ardelyx, Inc Company Information Table 76. Ardelyx, Inc Business Overview Table 77. Ardelyx, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ardelyx, Inc IBS-C Drugs Product Portfolio Table 79. Ardelyx, Inc Recent Development Table 80. Astellas Pharmaceuticals Company Information Table 81. Astellas Pharmaceuticals Business Overview Table 82. Astellas Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Astellas Pharmaceuticals IBS-C Drugs Product Portfolio Table 84. Astellas Pharmaceuticals Recent Development Table 85. Bama-Geve, SLU Company Information Table 86. Bama-Geve, SLU Business Overview Table 87. Bama-Geve, SLU IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Bama-Geve, SLU IBS-C Drugs Product Portfolio Table 89. Bama-Geve, SLU Recent Development Table 90. Catalent Pharmaceuticals Solutions Company Information Table 91. Catalent Pharmaceuticals Solutions Business Overview Table 92. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio Table 94. Catalent Pharmaceuticals Solutions Recent Development Table 95. Ferring BV Company Information Table 96. Ferring BV Business Overview Table 97. Ferring BV IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Ferring BV IBS-C Drugs Product Portfolio Table 99. Ferring BV Recent Development Table 100. Ironwood Pharmaceuticals, Inc Company Information Table 101. Ironwood Pharmaceuticals, Inc Business Overview Table 102. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio Table 104. Ironwood Pharmaceuticals, Inc Recent Development Table 105. Norgine B.V Company Information Table 106. Norgine B.V Business Overview Table 107. Norgine B.V IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Norgine B.V IBS-C Drugs Product Portfolio Table 109. Norgine B.V Recent Development Table 110. Novartis Pharma Ag Company Information Table 111. Novartis Pharma Ag Business Overview Table 112. Novartis Pharma Ag IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Novartis Pharma Ag IBS-C Drugs Product Portfolio Table 114. Novartis Pharma Ag Recent Development Table 115. Ono Pharmaceutical Co., Ltd Company Information Table 116. Ono Pharmaceutical Co., Ltd Business Overview Table 117. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio Table 119. Ono Pharmaceutical Co., Ltd Recent Development Table 120. Prometheus Laboratories Inc Company Information Table 121. Prometheus Laboratories Inc Business Overview Table 122. Prometheus Laboratories Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Prometheus Laboratories Inc IBS-C Drugs Product Portfolio Table 124. Prometheus Laboratories Inc Recent Development Table 125. Salix Pharmaceuticals Ltd Company Information Table 126. Salix Pharmaceuticals Ltd Business Overview Table 127. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio Table 129. Salix Pharmaceuticals Ltd Recent Development Table 130. Sucampo Pharmaceuticals Company Information Table 131. Sucampo Pharmaceuticals Business Overview Table 132. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio Table 134. Sucampo Pharmaceuticals Recent Development Table 135. Synergy Pharmaceuticals Company Information Table 136. Synergy Pharmaceuticals Business Overview Table 137. Synergy Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Synergy Pharmaceuticals IBS-C Drugs Product Portfolio Table 139. Synergy Pharmaceuticals Recent Development Table 140. Synthetic Biologics, Inc Company Information Table 141. Synthetic Biologics, Inc Business Overview Table 142. Synthetic Biologics, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Synthetic Biologics, Inc IBS-C Drugs Product Portfolio Table 144. Synthetic Biologics, Inc Recent Development Table 145. Teva Pharmaceutical Industries Company Information Table 146. Teva Pharmaceutical Industries Business Overview Table 147. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio Table 149. Teva Pharmaceutical Industries Recent Development Table 150. The Menarini Group Company Information Table 151. The Menarini Group Business Overview Table 152. The Menarini Group IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. The Menarini Group IBS-C Drugs Product Portfolio Table 154. The Menarini Group Recent Development Table 155. Yuhan Corp Company Information Table 156. Yuhan Corp Business Overview Table 157. Yuhan Corp IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Yuhan Corp IBS-C Drugs Product Portfolio Table 159. Yuhan Corp Recent Development Table 160. Astrazeneca Plc Company Information Table 161. Astrazeneca Plc Business Overview Table 162. Astrazeneca Plc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Astrazeneca Plc IBS-C Drugs Product Portfolio Table 164. Astrazeneca Plc Recent Development Table 165. Nestle Company Information Table 166. Nestle Business Overview Table 167. Nestle IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Nestle IBS-C Drugs Product Portfolio Table 169. Nestle Recent Development Table 170. North America IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 171. North America IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 172. North America IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 173. North America IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 174. North America IBS-C Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 175. North America IBS-C Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 176. North America IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 177. North America IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 178. North America IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 179. North America IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 180. North America IBS-C Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 181. North America IBS-C Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 182. North America IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. North America IBS-C Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. North America IBS-C Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. North America IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 186. North America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 187. North America IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 188. North America IBS-C Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 189. North America IBS-C Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 190. United States IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 191. Canada IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 192. Europe IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 193. Europe IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 194. Europe IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 195. Europe IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 196. Europe IBS-C Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 197. Europe IBS-C Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 198. Europe IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 199. Europe IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 200. Europe IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 201. Europe IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 202. Europe IBS-C Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 203. Europe IBS-C Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 204. Europe IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. Europe IBS-C Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. Europe IBS-C Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. Europe IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 208. Europe IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 209. Europe IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 210. Europe IBS-C Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 211. Europe IBS-C Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Germany IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 213. France IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 214. U.K. IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 215. Italy IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 216. Netherlands IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 217. Nordic Countries IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 218. China IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 219. China IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 220. China IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 221. China IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 222. China IBS-C Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 223. China IBS-C Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 224. China IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 225. China IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 226. China IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 227. China IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 228. China IBS-C Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 229. China IBS-C Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 230. Asia IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 231. Asia IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 232. Asia IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 233. Asia IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 234. Asia IBS-C Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 235. Asia IBS-C Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 236. Asia IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 237. Asia IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 238. Asia IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 239. Asia IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 240. Asia IBS-C Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 241. Asia IBS-C Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 242. Asia IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. Asia IBS-C Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. Asia IBS-C Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. Asia IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 246. Asia IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 247. Asia IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 248. Asia IBS-C Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 249. Asia IBS-C Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 250. Japan IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 251. South Korea IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 252. India IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 253. Australia IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 254. China Taiwan IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 255. Southeast Asia IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 256. SAMEA IBS-C Drugs Revenue by Type (2021-2026) & (US$ Million) Table 257. SAMEA IBS-C Drugs Revenue by Type (2027-2032) & (US$ Million) Table 258. SAMEA IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 259. SAMEA IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 260. SAMEA IBS-C Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 261. SAMEA IBS-C Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 262. SAMEA IBS-C Drugs Revenue by Application (2021-2026) & (US$ Million) Table 263. SAMEA IBS-C Drugs Revenue by Application (2027-2032) & (US$ Million) Table 264. SAMEA IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 265. SAMEA IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 266. SAMEA IBS-C Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 267. SAMEA IBS-C Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 268. SAMEA IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 269. SAMEA IBS-C Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 270. SAMEA IBS-C Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 271. SAMEA IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 272. SAMEA IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 273. SAMEA IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 274. SAMEA IBS-C Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 275. SAMEA IBS-C Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 276. Brazil IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 277. Argentina IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 278. Chile IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 279. Colombia IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 280. Peru IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 281. Saudi Arabia IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 282. Israel IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 283. UAE IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 284. Turkey IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 285. Iran IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 286. Egypt IBS-C Drugs Revenue (2021-2032) & (US$ Million) Table 287. Key Raw Materials Table 288. Raw Materials Key Suppliers Table 289. IBS-C Drugs Distributors List Table 290. IBS-C Drugs Customers List Table 291. Research Programs/Design for This Report Table 292. Authors List of This Report Table 293. Secondary Sources Table 294. Primary Sources List of Figures Figure 1. IBS-C Drugs Image Figure 2. Global IBS-C Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS-C Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Stimulant Laxatives Image Figure 5. Linaclotide Image Figure 6. Lubiprostone Image Figure 7. Osmotic Laxatives Image Figure 8. Others Image Figure 9. Global IBS-C Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global IBS-C Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Retail Pharmacies Image Figure 14. Global IBS-C Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global IBS-C Drugs Revenue (2021-2032) & (US$ Million) Figure 16. Global IBS-C Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global IBS-C Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global IBS-C Drugs Revenue Market Share by Region (2021-2032) Figure 19. Global IBS-C Drugs Sales (2021-2032) & (K Units) Figure 20. Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global IBS-C Drugs Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico IBS-C Drugs Sales YoY (2021-2032) & (K Units) Figure 23. Europe IBS-C Drugs Sales YoY (2021-2032) & (K Units) Figure 24. China IBS-C Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) IBS-C Drugs Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa IBS-C Drugs Sales YoY (2021-2032) & (K Units) Figure 27. Global IBS-C Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global IBS-C Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global IBS-C Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global IBS-C Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global IBS-C Drugs Revenue Market Share by Type (2021-2032) Figure 33. Global IBS-C Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global IBS-C Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global IBS-C Drugs Sales Market Share by Type (2021-2032) Figure 36. Global IBS-C Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global IBS-C Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global IBS-C Drugs Revenue Market Share by Application (2021-2032) Figure 39. Global IBS-C Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global IBS-C Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global IBS-C Drugs Sales Market Share by Application (2021-2032) Figure 42. North America IBS-C Drugs Revenue Share by Type (2021-2032) Figure 43. North America IBS-C Drugs Sales Share by Type (2021-2032) Figure 44. North America IBS-C Drugs Revenue Share by Application (2021-2032) Figure 45. North America IBS-C Drugs Sales Share by Application (2021-2032) Figure 46. North America IBS-C Drugs Revenue Share by Country (2021-2032) Figure 47. North America IBS-C Drugs Sales Share by Country (2021-2032) Figure 48. Europe IBS-C Drugs Revenue Share by Type (2021-2032) Figure 49. Europe IBS-C Drugs Sales Share by Type (2021-2032) Figure 50. Europe IBS-C Drugs Revenue Share by Application (2021-2032) Figure 51. Europe IBS-C Drugs Sales Share by Application (2021-2032) Figure 52. Europe IBS-C Drugs Revenue Share by Country (2021-2032) Figure 53. Europe IBS-C Drugs Sales Share by Country (2021-2032) Figure 54. China IBS-C Drugs Revenue Share by Type (2021-2032) Figure 55. China IBS-C Drugs Sales Share by Type (2021-2032) Figure 56. China IBS-C Drugs Revenue Share by Application (2021-2032) Figure 57. China IBS-C Drugs Sales Share by Application (2021-2032) Figure 58. Asia IBS-C Drugs Revenue Share by Type (2021-2032) Figure 59. Asia IBS-C Drugs Sales Share by Type (2021-2032) Figure 60. Asia IBS-C Drugs Revenue Share by Application (2021-2032) Figure 61. Asia IBS-C Drugs Sales Share by Application (2021-2032) Figure 62. Asia IBS-C Drugs Revenue Share by Country (2021-2032) Figure 63. Asia IBS-C Drugs Sales Share by Country (2021-2032) Figure 64. SAMEA IBS-C Drugs Revenue Share by Type (2021-2032) Figure 65. SAMEA IBS-C Drugs Sales Share by Type (2021-2032) Figure 66. SAMEA IBS-C Drugs Revenue Share by Application (2021-2032) Figure 67. SAMEA IBS-C Drugs Sales Share by Application (2021-2032) Figure 68. SAMEA IBS-C Drugs Revenue Share by Country (2021-2032) Figure 69. SAMEA IBS-C Drugs Sales Share by Country (2021-2032) Figure 70. IBS-C Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. IBS-C Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant Laxatives
  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott Laboratories
  • Actavis Nordic A/S
  • Albireo Pharma Inc
  • Ardelyx, Inc
  • Astellas Pharmaceuticals
  • Bama-Geve, SLU
  • Catalent Pharmaceuticals Solutions
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc
  • Norgine B.V
  • Novartis Pharma Ag
  • Ono Pharmaceutical Co., Ltd
  • Prometheus Laboratories Inc
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc
  • Teva Pharmaceutical Industries
  • The Menarini Group
  • Yuhan Corp
  • Astrazeneca Plc
  • Nestle

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 IBS-C Drugs Market by Type
  3. 1.2.1 Global IBS-C Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Stimulant Laxatives
  5. 1.2.3 Linaclotide
  6. 1.2.4 Lubiprostone
  7. 1.2.5 Osmotic Laxatives
  8. 1.2.6 Others
  9. 1.3 IBS-C Drugs Market by Application
  10. 1.3.1 Global IBS-C Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Retail Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 IBS-C Drugs Market Dynamics
  1. 2.1 IBS-C Drugs Industry Trends
  2. 2.2 IBS-C Drugs Industry Drivers
  3. 2.3 IBS-C Drugs Industry Opportunities and Challenges
  4. 2.4 IBS-C Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global IBS-C Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global IBS-C Drugs Revenue by Region
  3. 3.2.1 Global IBS-C Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global IBS-C Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global IBS-C Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global IBS-C Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global IBS-C Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global IBS-C Drugs Sales by Region
  9. 3.4.1 Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global IBS-C Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global IBS-C Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global IBS-C Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global IBS-C Drugs Revenue by Manufacturers
  2. 4.1.1 Global IBS-C Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global IBS-C Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global IBS-C Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global IBS-C Drugs Sales by Manufacturers
  6. 4.2.1 Global IBS-C Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global IBS-C Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global IBS-C Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global IBS-C Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global IBS-C Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global IBS-C Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global IBS-C Drugs Manufacturers, Product Type & Application
  13. 4.7 Global IBS-C Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global IBS-C Drugs Market CR5 and HHI
  16. 4.8.2 2025 IBS-C Drugs Tier 1, Tier 2, and Tier 3
5 IBS-C Drugs Market by Type
  1. 5.1 Global IBS-C Drugs Revenue by Type
  2. 5.1.1 Global IBS-C Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global IBS-C Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global IBS-C Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global IBS-C Drugs Sales by Type
  6. 5.2.1 Global IBS-C Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IBS-C Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global IBS-C Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global IBS-C Drugs Price by Type
6 IBS-C Drugs Market by Application
  1. 6.1 Global IBS-C Drugs Revenue by Application
  2. 6.1.1 Global IBS-C Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global IBS-C Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global IBS-C Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global IBS-C Drugs Sales by Application
  6. 6.2.1 Global IBS-C Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global IBS-C Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global IBS-C Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global IBS-C Drugs Price by Application
7 Company Profiles
  1. 7.1 Abbott Laboratories
  2. 7.1.1 Abbott Laboratories Company Information
  3. 7.1.2 Abbott Laboratories Business Overview
  4. 7.1.3 Abbott Laboratories IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Laboratories IBS-C Drugs Product Portfolio
  6. 7.1.5 Abbott Laboratories Recent Developments
  7. 7.2 Actavis Nordic A/S
  8. 7.2.1 Actavis Nordic A/S Company Information
  9. 7.2.2 Actavis Nordic A/S Business Overview
  10. 7.2.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
  12. 7.2.5 Actavis Nordic A/S Recent Developments
  13. 7.3 Albireo Pharma Inc
  14. 7.3.1 Albireo Pharma Inc Company Information
  15. 7.3.2 Albireo Pharma Inc Business Overview
  16. 7.3.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
  18. 7.3.5 Albireo Pharma Inc Recent Developments
  19. 7.4 Ardelyx, Inc
  20. 7.4.1 Ardelyx, Inc Company Information
  21. 7.4.2 Ardelyx, Inc Business Overview
  22. 7.4.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
  24. 7.4.5 Ardelyx, Inc Recent Developments
  25. 7.5 Astellas Pharmaceuticals
  26. 7.5.1 Astellas Pharmaceuticals Company Information
  27. 7.5.2 Astellas Pharmaceuticals Business Overview
  28. 7.5.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
  30. 7.5.5 Astellas Pharmaceuticals Recent Developments
  31. 7.6 Bama-Geve, SLU
  32. 7.6.1 Bama-Geve, SLU Company Information
  33. 7.6.2 Bama-Geve, SLU Business Overview
  34. 7.6.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
  36. 7.6.5 Bama-Geve, SLU Recent Developments
  37. 7.7 Catalent Pharmaceuticals Solutions
  38. 7.7.1 Catalent Pharmaceuticals Solutions Company Information
  39. 7.7.2 Catalent Pharmaceuticals Solutions Business Overview
  40. 7.7.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
  42. 7.7.5 Catalent Pharmaceuticals Solutions Recent Developments
  43. 7.8 Ferring BV
  44. 7.8.1 Ferring BV Company Information
  45. 7.8.2 Ferring BV Business Overview
  46. 7.8.3 Ferring BV IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Ferring BV IBS-C Drugs Product Portfolio
  48. 7.8.5 Ferring BV Recent Developments
  49. 7.9 Ironwood Pharmaceuticals, Inc
  50. 7.9.1 Ironwood Pharmaceuticals, Inc Company Information
  51. 7.9.2 Ironwood Pharmaceuticals, Inc Business Overview
  52. 7.9.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
  54. 7.9.5 Ironwood Pharmaceuticals, Inc Recent Developments
  55. 7.10 Norgine B.V
  56. 7.10.1 Norgine B.V Company Information
  57. 7.10.2 Norgine B.V Business Overview
  58. 7.10.3 Norgine B.V IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Norgine B.V IBS-C Drugs Product Portfolio
  60. 7.10.5 Norgine B.V Recent Developments
  61. 7.11 Novartis Pharma Ag
  62. 7.11.1 Novartis Pharma Ag Company Information
  63. 7.11.2 Novartis Pharma Ag Business Overview
  64. 7.11.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
  66. 7.11.5 Novartis Pharma Ag Recent Developments
  67. 7.12 Ono Pharmaceutical Co., Ltd
  68. 7.12.1 Ono Pharmaceutical Co., Ltd Company Information
  69. 7.12.2 Ono Pharmaceutical Co., Ltd Business Overview
  70. 7.12.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
  72. 7.12.5 Ono Pharmaceutical Co., Ltd Recent Developments
  73. 7.13 Prometheus Laboratories Inc
  74. 7.13.1 Prometheus Laboratories Inc Company Information
  75. 7.13.2 Prometheus Laboratories Inc Business Overview
  76. 7.13.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
  78. 7.13.5 Prometheus Laboratories Inc Recent Developments
  79. 7.14 Salix Pharmaceuticals Ltd
  80. 7.14.1 Salix Pharmaceuticals Ltd Company Information
  81. 7.14.2 Salix Pharmaceuticals Ltd Business Overview
  82. 7.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
  84. 7.14.5 Salix Pharmaceuticals Ltd Recent Developments
  85. 7.15 Sucampo Pharmaceuticals
  86. 7.15.1 Sucampo Pharmaceuticals Company Information
  87. 7.15.2 Sucampo Pharmaceuticals Business Overview
  88. 7.15.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
  90. 7.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 7.16 Synergy Pharmaceuticals
  92. 7.16.1 Synergy Pharmaceuticals Company Information
  93. 7.16.2 Synergy Pharmaceuticals Business Overview
  94. 7.16.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
  96. 7.16.5 Synergy Pharmaceuticals Recent Developments
  97. 7.17 Synthetic Biologics, Inc
  98. 7.17.1 Synthetic Biologics, Inc Company Information
  99. 7.17.2 Synthetic Biologics, Inc Business Overview
  100. 7.17.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
  102. 7.17.5 Synthetic Biologics, Inc Recent Developments
  103. 7.18 Teva Pharmaceutical Industries
  104. 7.18.1 Teva Pharmaceutical Industries Company Information
  105. 7.18.2 Teva Pharmaceutical Industries Business Overview
  106. 7.18.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
  108. 7.18.5 Teva Pharmaceutical Industries Recent Developments
  109. 7.19 The Menarini Group
  110. 7.19.1 The Menarini Group Company Information
  111. 7.19.2 The Menarini Group Business Overview
  112. 7.19.3 The Menarini Group IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 The Menarini Group IBS-C Drugs Product Portfolio
  114. 7.19.5 The Menarini Group Recent Developments
  115. 7.20 Yuhan Corp
  116. 7.20.1 Yuhan Corp Company Information
  117. 7.20.2 Yuhan Corp Business Overview
  118. 7.20.3 Yuhan Corp IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Yuhan Corp IBS-C Drugs Product Portfolio
  120. 7.20.5 Yuhan Corp Recent Developments
  121. 7.21 Astrazeneca Plc
  122. 7.21.1 Astrazeneca Plc Company Information
  123. 7.21.2 Astrazeneca Plc Business Overview
  124. 7.21.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
  126. 7.21.5 Astrazeneca Plc Recent Developments
  127. 7.22 Nestle
  128. 7.22.1 Nestle Company Information
  129. 7.22.2 Nestle Business Overview
  130. 7.22.3 Nestle IBS-C Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Nestle IBS-C Drugs Product Portfolio
  132. 7.22.5 Nestle Recent Developments
8 North America
  1. 8.1 North America IBS-C Drugs Market Size by Type
  2. 8.1.1 North America IBS-C Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America IBS-C Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America IBS-C Drugs Price by Type (2021-2032)
  5. 8.2 North America IBS-C Drugs Market Size by Application
  6. 8.2.1 North America IBS-C Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America IBS-C Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America IBS-C Drugs Price by Application (2021-2032)
  9. 8.3 North America IBS-C Drugs Market Size by Country
  10. 8.3.1 North America IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America IBS-C Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe IBS-C Drugs Market Size by Type
  2. 9.1.1 Europe IBS-C Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe IBS-C Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe IBS-C Drugs Price by Type (2021-2032)
  5. 9.2 Europe IBS-C Drugs Market Size by Application
  6. 9.2.1 Europe IBS-C Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe IBS-C Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe IBS-C Drugs Price by Application (2021-2032)
  9. 9.3 Europe IBS-C Drugs Market Size by Country
  10. 9.3.1 Europe IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe IBS-C Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China IBS-C Drugs Market Size by Type
  2. 10.1.1 China IBS-C Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China IBS-C Drugs Sales by Type (2021-2032)
  4. 10.1.3 China IBS-C Drugs Price by Type (2021-2032)
  5. 10.2 China IBS-C Drugs Market Size by Application
  6. 10.2.1 China IBS-C Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China IBS-C Drugs Sales by Application (2021-2032)
  8. 10.2.3 China IBS-C Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia IBS-C Drugs Market Size by Type
  2. 11.1.1 Asia IBS-C Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia IBS-C Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia IBS-C Drugs Price by Type (2021-2032)
  5. 11.2 Asia IBS-C Drugs Market Size by Application
  6. 11.2.1 Asia IBS-C Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia IBS-C Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia IBS-C Drugs Price by Application (2021-2032)
  9. 11.3 Asia IBS-C Drugs Market Size by Country
  10. 11.3.1 Asia IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia IBS-C Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA IBS-C Drugs Market Size by Type
  2. 12.1.1 SAMEA IBS-C Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA IBS-C Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA IBS-C Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA IBS-C Drugs Market Size by Application
  6. 12.2.1 SAMEA IBS-C Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA IBS-C Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA IBS-C Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA IBS-C Drugs Market Size by Country
  10. 12.3.1 SAMEA IBS-C Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA IBS-C Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA IBS-C Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 IBS-C Drugs Value Chain Analysis
  2. 13.1.1 IBS-C Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 IBS-C Drugs Production Mode & Process
  6. 13.2 IBS-C Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 IBS-C Drugs Distributors
  9. 13.2.3 IBS-C Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst